UNSPSC 51323202: Nicanartine

This classification denotes an antioxidant and anti-lipidemic agent with the molecular formula C23H33NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85DV2PAF78, chemically known as 2,6-di-tert-butyl-4-(3-(3-pyridylmethoxy)propyl)phenol but generally known as nicanartine, which bears US NIH Compound Identifier 66001. European Medicines Agency schedules Nicanartine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09223MIG.

UNSPSC 51323202 Nicanartine, a Commodity code, encompasses emergency medications and pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and institutional healthcare operations. Recent solicitations show state and local buyers purchasing life support medications, generic pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. The issuing bodies include city fire departments (Tampa Fire Rescue via the City of Tampa's Purchasing Department), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). Work solicited ranges from sealed-bid procurement of specific medication line items with firm pricing and expedited delivery to market-intelligence gathering on direct-to-manufacturer prescription fulfillment models and competitive RFPs for generic multi-source pharmaceutical supply agreements with authorized wholesalers.

Recent activity spans Florida, Texas, and Minnesota-led cooperative purchasing regions. The City of Tampa issued IFB No. 26P00188 on April 24, 2026, for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) with a due date of April 8, 2026, estimated contract value of $40,000, a one-year term with two optional renewals, and a 5 percent SLBE bid discount; the award was to be made within 120 days to the lowest responsive, responsible bidder. The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs for self-insured employer and state agency health plans, with responses due April 3, 2026. The Minnesota Department of Administration's MMCAP issued RFP No. S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026, effective July 1, 2026, a two-year initial term, evaluation weighted 75 percent on price competitiveness, and vendors required to maintain $5 million in commercial general liability and $2 million in network security and privacy liability coverage.